Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine blocks voltage‑gated sodium channels on nerve fibers, preventing the generation and transmission of nerve impulses. The accompanying epinephrine causes local blood‑vessel constriction, which prolongs the anesthetic effect and reduces systemic absorption, resulting in a focused, temporary numbness of the treated area.

The exact dose of Orabloc is determined by the prescribing dentist based on the specific procedure, patient age, weight, and health status. Dental professionals calculate the appropriate volume and concentration to achieve effective anesthesia while staying within safe limits.

The pregnancy safety category for Orabloc is not established. It should only be used during pregnancy or lactation when the expected benefit justifies any potential risk to the mother or infant, and after a careful assessment by the treating clinician.

To order Orabloc, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Both Orabloc (articaine) and lidocaine are amide‑type dental anesthetics, but articaine has a higher lipid solubility and a thiophene ring, which can provide faster onset and deeper penetration in dense bone. Lidocaine is longer established, while articaine may be preferred for procedures requiring rapid anesthesia with a slightly shorter duration.

Orabloc should be stored at room temperature, below 25 °C, in its original packaging. Keep the vial protected from direct light and moisture. Do not freeze or expose it to extreme temperatures, and ensure the container is sealed when not in use.

Orabloc is administered by a qualified dental professional as a local injection into the soft tissues surrounding the tooth or surgical site. The solution is typically delivered using a sterile syringe and needle, following aseptic technique and appropriate dosage calculations.

The most serious risks include an allergic reaction that can progress to anaphylaxis, cardiovascular toxicity from the epinephrine component (such as severe hypertension or arrhythmia), and, rarely, methemoglobinemia or seizure activity. Immediate medical attention is required if any of these symptoms appear.

Orabloc should be avoided in individuals with a known hypersensitivity to articaine, other amide‑type local anesthetics, or epinephrine. It is also contraindicated in patients with uncontrolled severe cardiac disease, significant hypertension, or those taking non‑selective MAO inhibitors without careful medical supervision.